Ezeb v. Sandoz Pharmaceuticals

192 So. 3d 756, 2016 La. LEXIS 1420, 2016 WL 3513429
CourtSupreme Court of Louisiana
DecidedJune 3, 2016
DocketNo. 2016-CC-0886
StatusPublished

This text of 192 So. 3d 756 (Ezeb v. Sandoz Pharmaceuticals) is published on Counsel Stack Legal Research, covering Supreme Court of Louisiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ezeb v. Sandoz Pharmaceuticals, 192 So. 3d 756, 2016 La. LEXIS 1420, 2016 WL 3513429 (La. 2016).

Opinion

In re Novartis Pharmaceuticals Corporation, successor by merger to Sandoz Pharmaceuticals Corporation; — Defendant; Applying For Writ of Certiorari and/or Review, Parish of Orleans, Civil District Court Div. A, No. 92-20622; to the Court of Appeal, Fourth Circuit, No. 2016-C-0428.

Granted. Under the unique facts presented, the district court did not abuse its great discretion in granting relator’s motion. Accordingly, the judgment of the court of appeal is reversed, and the judgment of the district court is reinstated.

JOHNSON, C.J., KNOLL and CLARK, JJ., would deny.

Free access — add to your briefcase to read the full text and ask questions with AI

Cite This Page — Counsel Stack

Bluebook (online)
192 So. 3d 756, 2016 La. LEXIS 1420, 2016 WL 3513429, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ezeb-v-sandoz-pharmaceuticals-la-2016.